Iovance Biotherapeutics, Inc.

IOVA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$372-$444-$396-$342
Dep. & Amort.$44$33$21$14
Deferred Tax-$3-$3$0$0
Stock-Based Comp.$110$63$84$70
Change in WC-$123-$7-$3$25
Other Non-Cash-$9-$4$1$6
Operating Cash Flow-$353-$362-$293-$228
Investing Activities
PP&E Inv.-$11-$22-$20-$38
Net Acquisitions-$53-$213-$277-$38
Inv. Purchases-$461-$206-$246-$725
Inv. Sales/Matur.$428$286$523$763
Other Inv. Act.$0$0$277$38
Investing Cash Flow-$96-$155$256$0
Financing Activities
Debt Repay.$0$0$0$1
Stock Issued$397$463$190$203
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$7-$0$1$35
Financing Cash Flow$391$463$190$239
Forex Effect-$1-$3$0$0
Net Chg. in Cash-$59-$57$154$11
Supplemental Information
Beg. Cash$181$238$84$73
End Cash$122$181$238$84
Free Cash Flow-$364-$384-$313-$266
Iovance Biotherapeutics, Inc. (IOVA) Financial Statements & Key Stats | AlphaPilot